<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971109</url>
  </required_header>
  <id_info>
    <org_study_id>SIGA-246-024</org_study_id>
    <nct_id>NCT04971109</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of TPOXX When Administered Orally for 28 Days in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIGA Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical CBRN Defense Consortium (MCDC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>SIGA Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when&#xD;
      administered BID for 28 days in adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to assess&#xD;
      the safety, tolerability, and PK of oral TPOXX 600 mg when administered BID for 28 days in&#xD;
      adult subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>An oral dose of placebo (3 capsules identical to TPOXX)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>clinical laboratory tests</measure>
    <time_frame>60 days</time_frame>
    <description>Incidence of abnormal clinical laboratory (chemistry, hematology and urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>60 days</time_frame>
    <description>systolic and diastolic blood pressure measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>60 days</time_frame>
    <description>heart rate per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>respiratory rate</measure>
    <time_frame>60 days</time_frame>
    <description>respiratory rate per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>body temperature</measure>
    <time_frame>60 days</time_frame>
    <description>body temperature measured in celcius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Exam findings; abnormalities reported</measure>
    <time_frame>60 days</time_frame>
    <description>evaluation of head, ears, eyes, nose, and throat; cardiac (including auscultation of heart); pulmonary (chest) auscultation of lungs; abdomen; skin; musculoskeletal system; lymphatic system; and neurologic system (cranial nerves, sensation, motor function, coordination, reflexes, and mental status).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>60 days</time_frame>
    <description>12-lead ECG Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PR interval</measure>
    <time_frame>60 days</time_frame>
    <description>12-lead ECG Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QRS interval</measure>
    <time_frame>60 days</time_frame>
    <description>12-lead ECG Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QT interval</measure>
    <time_frame>60 days</time_frame>
    <description>12-lead ECG Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc interval</measure>
    <time_frame>60 days</time_frame>
    <description>12-lead ECG Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcF interval</measure>
    <time_frame>60 days</time_frame>
    <description>12-lead ECG Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RR Duration</measure>
    <time_frame>60 days</time_frame>
    <description>12-lead ECG Measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCO24</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC time zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC tau</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC time zero to tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 28</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg</measure>
    <time_frame>Day 28</time_frame>
    <description>Average steady-state plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Day 28</time_frame>
    <description>Trough plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>Day 28</time_frame>
    <description>Minimum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 28</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCO24</measure>
    <time_frame>Day 28</time_frame>
    <description>AUC time zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Day 28</time_frame>
    <description>AUC time zero to tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCO-last</measure>
    <time_frame>Day 28</time_frame>
    <description>AUC from time zero to last measurable sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC-∞</measure>
    <time_frame>Day 28</time_frame>
    <description>AUC from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Day 28</time_frame>
    <description>Observed elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 28</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F</measure>
    <time_frame>Day 28</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day 28</time_frame>
    <description>Apparent volume distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac</measure>
    <time_frame>Day 28</time_frame>
    <description>Accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%Fluctuation</measure>
    <time_frame>Day 28</time_frame>
    <description>percent of fluctuation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">445</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>TPOXX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Group 1: An oral dose of 600 mg (3 × 200 mg capsules) TPOXX BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPOXX Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Group 2: An oral dose of placebo (3 capsules identical to TPOXX) BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPOXX</intervention_name>
    <description>Study is based on Animal Regulatory Rule</description>
    <arm_group_label>TPOXX</arm_group_label>
    <other_name>tecovirimat</other_name>
    <other_name>ST-246</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TPOXX Placebo</intervention_name>
    <description>Does not apply</description>
    <arm_group_label>TPOXX Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male or female between 18 and 80 years of age, inclusive.&#xD;
&#xD;
          2. Subject is available for clinical follow-up for the duration of the study.&#xD;
&#xD;
          3. Women of childbearing potential have a negative beta human chorionic gonadotropin&#xD;
             pregnancy test (serum) at the screening visit and a confirmatory negative pregnancy&#xD;
             test on Day 1 or Day -1 (PK subset) before receipt of study drug, and meet one of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Subject or their partner has undergone surgical sterilization.&#xD;
&#xD;
               2. Subject is postmenopausal, defined as 12 consecutive months with no menses&#xD;
                  without an alternative medical cause and has a documented plasma follicle&#xD;
                  stimulating hormone level &gt;40 IU/mL.&#xD;
&#xD;
               3. Subject agrees to be abstinent (ie, heterosexually inactive) for the duration of&#xD;
                  the study.&#xD;
&#xD;
               4. Subject agrees to consistently use 1 of the following methods of contraception&#xD;
                  from the beginning of screening (which they had been consistently using for at&#xD;
                  least 30 days before the first dose of study drug) through 30 days after the last&#xD;
                  dose of study drug:&#xD;
&#xD;
             i. Condoms, male or female, with a spermicide NOTE: For male subjects, condoms must be&#xD;
             used for 90 days after the last dose of study drug. Male and female condoms should not&#xD;
             be used together, as this can reduce their effectiveness.&#xD;
&#xD;
             ii. Diaphragm or cervical cap with spermicide iii. Intrauterine device with spermicide&#xD;
             iv. Oral contraceptives or other hormonal methods NOTE: Another nonhormonal method of&#xD;
             contraception must be used in conjunction with oral contraceptives.&#xD;
&#xD;
             v. Male sexual partner who had undergone a vasectomy at least 3 months before&#xD;
             screening&#xD;
&#xD;
          4. Male subjects must agree to not donate sperm from the first dose of study drug through&#xD;
             90 days after the last dose of study drug.&#xD;
&#xD;
          5. Subject is considered by the investigator to be in good general health as determined&#xD;
             by medical history (no hospitalizations for chronic medical conditions in the previous&#xD;
             2 years), clinical laboratory test results, vital sign measurements, 12-lead ECG&#xD;
             results, and physical examination findings at screening.&#xD;
&#xD;
          6. Subject agrees not to use nicotine products, including electronic vapor cigarettes,&#xD;
             nicotine patches, or nicotine gum, for at least 30 days before the Day 1 randomization&#xD;
             visit through completion of the Day 29 dosing complete/ET visit.&#xD;
&#xD;
          7. Subject agrees to comply with the study dietary requirements throughout the study drug&#xD;
             dosing period.&#xD;
&#xD;
          8. Subject agrees not to consume caffeine- or xanthine-containing products during all&#xD;
             study visits, including overnight stays (PK subset); sodas, coffee, and tea designated&#xD;
             as caffeine free or noncaffeinated may be consumed on study days; caffeine may be&#xD;
             consumed while at home and between study visits.&#xD;
&#xD;
          9. Subject agrees to comply with all protocol requirements.&#xD;
&#xD;
         10. Subject has adequate venous access if participating in the PK subset.&#xD;
&#xD;
         11. Subject is able and willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is a female who is pregnant or breastfeeding or planning to become pregnant&#xD;
             within 3 months after the last dose of study drug.&#xD;
&#xD;
          2. Subject has a history of any clinically significant conditions including:&#xD;
&#xD;
               -  Asthma treated with oral systemic steroids within the past 6 months&#xD;
&#xD;
               -  Diabetes mellitus (type 1 or 2), with the exception of gestational diabetes&#xD;
&#xD;
               -  Hypertension that is poorly controlled (repeat readings &gt;140 mm Hg systolic&#xD;
                  and/or &gt;90 mmHg diastolic)&#xD;
&#xD;
               -  Thyroidectomy or thyroid disease that required medication within the past 12&#xD;
                  months&#xD;
&#xD;
               -  Serious angioedema episodes within the previous 3 years or requiring medication&#xD;
                  in the previous 2 years&#xD;
&#xD;
               -  History of head trauma resulting in a diagnosis of traumatic brain injury other&#xD;
                  than concussion&#xD;
&#xD;
               -  Frequent episodes of headache&#xD;
&#xD;
          3. Subject has received any vaccination within 28 days prior to Day 1 or plans to receive&#xD;
             a vaccination at any time during the treatment period or within 28 days after study&#xD;
             Day 28.&#xD;
&#xD;
          4. Subject has received treatment in another clinical study of an investigational drug&#xD;
             (or medical device) or investigational vaccine within 30 days or 5 half-lives&#xD;
             (whichever is longer) before the first dose of study drug.&#xD;
&#xD;
          5. Subject has a history of relevant drug and/or food allergies (ie, allergy to TPOXX or&#xD;
             excipients, or any significant food allergy that could preclude a standard diet in the&#xD;
             clinical investigative site).&#xD;
&#xD;
          6. Subject has any condition possibly affecting drug absorption (eg, previous surgery on&#xD;
             the gastrointestinal tract, including removal of parts of the stomach, bowel, liver,&#xD;
             gallbladder, or pancreas, with the exception of appendectomy).&#xD;
&#xD;
          7. Subject has evidence or history of clinically significant allergic (except for&#xD;
             untreated, asymptomatic, seasonal allergies at time of the first dose of study drug),&#xD;
             hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,&#xD;
             psychiatric, or neurological disease. Exceptions to these criteria (eg, stable, mild&#xD;
             joint disease unassociated with collagen vascular disease) may be made following&#xD;
             discussions with the medical monitor.&#xD;
&#xD;
          8. Subject has a history of cardiac disease, symptomatic or asymptomatic arrhythmias,&#xD;
             syncopal episodes, or risk factors for torsades de pointes (eg, heart failure,&#xD;
             hypokalemia).&#xD;
&#xD;
          9. Subject has a family history of sudden cardiac death not clearly due to acute&#xD;
             myocardial infarction.&#xD;
&#xD;
         10. Subject is 20 years of age or older and has a ≥10% risk of developing a myocardial&#xD;
             infarction or coronary death within the next 10 years using the National Cholesterol&#xD;
             Education Program's Risk Assessment Tool:&#xD;
             https://www.mcw.edu/calculators/ldl-cholesterol-goal-level.&#xD;
&#xD;
         11. Subject has a seizure disorder or history of seizures (does not include childhood&#xD;
             febrile seizures) or a past history that increases seizure risks such as significant&#xD;
             head injury that caused loss of consciousness or other changes in the subject's daily&#xD;
             function, concussion, stroke, central nervous system infection or disease, or alcohol&#xD;
             or drug abuse or family history of idiopathic seizures.&#xD;
&#xD;
         12. Subject has a history of a peptic ulcer or significant gastrointestinal bleeding.&#xD;
&#xD;
         13. Subject has a bleeding disorder diagnosed by a doctor (eg, factor deficiency,&#xD;
             coagulopathy, or platelet disorder requiring special precautions) or significant&#xD;
             bruising or bleeding difficulties with blood draws.&#xD;
&#xD;
         14. Subject has a malignancy that is active or treated malignancy for which there is not&#xD;
             reasonable assurance of sustained cure, or malignancy that is likely to recur during&#xD;
             the period of the study (subject should be in complete remission for at least 5&#xD;
             years).&#xD;
&#xD;
         15. Subject has neutropenia or other blood dyscrasia determined to be clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
         16. Subject has used any of the following prohibited medications from within 7 days (or 5&#xD;
             half lives, whichever is longer) before the first dose of study drug: antidiabetic&#xD;
             medication; anticoagulants; anticonvulsants; substrates of the breast cancer&#xD;
             resistance protein transporter including methotrexate, mitoxantrone, imatinib,&#xD;
             irinotecan, lapatinib, rosuvastatin, sulfasalazine, and topotecan; substrates of&#xD;
             cytochromes (CYP)2C8 including repaglinide, paclitaxel, montelukast, pioglitazone,&#xD;
             rosiglitazone; and substrates of CYP2C19 including S-mephenytoin, clobazam, diazepam,&#xD;
             rabeprazole, voriconazole, lansoprazole, and omeprazole. Medications not listed here&#xD;
             that are known (or thought) to be CYP3A4 substrates may be allowed at the&#xD;
             investigator's discretion, after consultation with the medical monitor, if&#xD;
             administration poses little to no risk to the subject.&#xD;
&#xD;
         17. Subject has a history of drug or alcohol abuse or dependency within the last year&#xD;
             before screening.&#xD;
&#xD;
         18. Subject has a current or recent (&lt;30 days before screening) history of clinically&#xD;
             significant bacterial, fungal, or mycobacterial infection.&#xD;
&#xD;
         19. Subject has a current clinically significant viral infection.&#xD;
&#xD;
         20. Subject has a known clinically significant chronic viral infection (eg, human T cell&#xD;
             lymphotropic virus I or II).&#xD;
&#xD;
         21. Subject demonstrates long-term use (≥14 consecutive days) of glucocorticoids,&#xD;
             including oral or parenteral prednisone or equivalent (&gt;20 mg total dose per day), or&#xD;
             high dose inhaled steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent)&#xD;
             within the preceding 1 month (low dose [≤800 mcg/day of beclomethasone dipropionate or&#xD;
             equivalent] inhaled and topical steroids are allowed).&#xD;
&#xD;
         22. Subject has donated &gt;450 mL blood or blood components within 30 days before the first&#xD;
             dose of study drug. The investigator should instruct subjects who participate in this&#xD;
             study to not donate blood or blood components for 4 weeks after the completion of the&#xD;
             study.&#xD;
&#xD;
         23. Subject reports participation in strenuous activity or contact sports within 24 hours&#xD;
             before the first dose of study drug.&#xD;
&#xD;
         24. Subject has known hepatitis B or C infection or positive test for hepatitis B surface&#xD;
             antigen, hepatitis C virus antibody, or human immunodeficiency virus type 1 or 2&#xD;
             antibodies at screening.&#xD;
&#xD;
         25. Subject has a positive test result for amphetamines (including methamphetamines and&#xD;
             ecstasy/methylenedioxymethamphetamine), barbiturates, benzodiazepines, cannabinoids&#xD;
             (including tetrahydrocannabinol), cocaine metabolites, opiates (including heroin,&#xD;
             codeine, and oxycodone), cotinine, or alcohol at screening or check-in.&#xD;
&#xD;
         26. Subject has any of the following laboratory test results within 28 days before the&#xD;
             first dose of study drug:&#xD;
&#xD;
               -  Estimated serum creatinine clearance (Cockcroft Gault) &lt;70 mL/min&#xD;
&#xD;
               -  Creatinine in males &gt;1.7 mg/dL and in females &gt;1.4 mg/dL (1.3 times the upper&#xD;
                  laboratory reference range)&#xD;
&#xD;
               -  Hemoglobin ≤10% of the lower laboratory reference range&#xD;
&#xD;
               -  White blood cell counts considered to be clinically significant by the&#xD;
                  investigator&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1000 cells/mm3&#xD;
&#xD;
               -  Platelets not within ±10% of laboratory reference range&#xD;
&#xD;
               -  Alanine aminotransferase &gt;2 times above the upper laboratory reference range&#xD;
&#xD;
               -  Aspartate aminotransferase &gt;2 times above the upper laboratory reference range&#xD;
&#xD;
               -  Alkaline phosphatase &gt;20% above the upper laboratory reference range&#xD;
&#xD;
               -  Hemoglobin A1c ≥7.0%&#xD;
&#xD;
               -  Cholesterol ≥300 mg/dL and low density lipoprotein ≥190 mg/dL&#xD;
&#xD;
         27. Subject has a blood pressure considered to be clinically significant by the&#xD;
             investigator. Blood pressure may be retested twice in the sitting position at 5-minute&#xD;
             intervals.&#xD;
&#xD;
         28. Subject has a resting heart rate of &lt;40 beats per minute or &gt;110 beats per minute at&#xD;
             screening.&#xD;
&#xD;
         29. Subject has an abnormal ECG at screening that is determined by the investigator to be&#xD;
             clinically significant.&#xD;
&#xD;
         30. Male subject has a QT interval corrected using Fridericia's formula (QTcF) &gt;450 ms or&#xD;
             female subject has a QTcF &gt;470 ms at screening or Day 1, or Day -1 (PK subset).&#xD;
&#xD;
         31. Subject has used any prescription antiviral drugs with the intention of coronavirus&#xD;
             disease (COVID 19) prophylaxis, including those that are thought to be effective for&#xD;
             prevention of COVID 19 but have not been licensed for this indication, within 1 month&#xD;
             prior to study entry or during the study.&#xD;
&#xD;
         32. Subject is at a high risk of contracting SARS-CoV-2/COVID-19 infection, including, but&#xD;
             not limited to, individuals with known close contact with:&#xD;
&#xD;
               1. Anyone residing in, visiting, or working at a health care or long-term care&#xD;
                  institution (ie, long-term care facilities, acute care hospitals, rehabilitation&#xD;
                  hospitals, mental health hospitals, emergency departments)&#xD;
&#xD;
               2. Anyone with known history of COVID-19 within 2 weeks prior to study entry&#xD;
&#xD;
               3. Anyone who traveled outside the United States or has recently traveled outside of&#xD;
                  the state and has returned from a state that is listed on a travel advisory list&#xD;
                  requiring quarantine for any duration within 30 days before study entry&#xD;
&#xD;
         33. In the opinion of the investigator, the subject is not suitable for entry into the&#xD;
             study.&#xD;
&#xD;
         34. Subject is a member or family member of the investigator or study site personnel.&#xD;
&#xD;
         35. Subject has previously participated in this or any other clinical trial involving&#xD;
             TPOXX (tecovirimat).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Meara</last_name>
    <role>Study Director</role>
    <affiliation>SIGA Technologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Meara</last_name>
    <phone>5412464367</phone>
    <email>imeara@siga.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

